Hari Anant Deshpande, MD

Associate Professor of Medicine (Medical Oncology) and Assistant Professor of Surgery (Otolaryngology) and Assistant Clinical Professor of Nursing

Clinical Interests

  • Medical Oncology
  • Sarcoma

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Endocrine Oncology Program | Head and Neck Cancer Surgery Program | Prostate and Urologic Cancers Program

General Urology

Medical Oncology: Subset Medical Oncology Faculty

Medical Oncology

Yale Medical Group

Board Certifications

  • Hematology (Internal Medicine) AB of Internal Medicine (1998)

  • Internal Medicine AB of Internal Medicine (1995)

  • Medical Oncology AB of Internal Medicine (1999)

Clinical Trials

Conditions Study Title
Larynx, Lip, Oral Cavity and Pharynx RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer {CIRB}
Prostate Genitourinary Cancer Data and Specimen Repository
Brain and Nervous System, Other Respiratory and Intrathoracic Organs A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma
Larynx, Lip, Oral Cavity and Pharynx Yale Head and Neck Tissue Biorepository
Breast - Female SINGLE ARM, NEOADJUVANT, PHASE II TRIAL OF PERTUZUMAB AND TRASTUZUMAB ADMINISTERED CONCOMITANTLY WITH WEEKLY PACLITAXEL AND FEC FOR CLINICAL STAGE I-III HER2-POSITIVE BREAST CANCER
Bladder A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects with Metastatic Urothelial Cancer
Prostate Bayer 16544: A randomized open-label phase IIa study evaluating the efficacy and safety of radium-223 dichloride in combination with abiraterone acetate or enzalutamide in subjects with castration-resistant prostate cancer (CRPC) who have bone metastases
Prostate SWOG S1216: A PHASE III RANDOMIZED TRIAL COMPARING ANDROGEN DEPRIVATION THERAPY + TAK-700 WITH ANDROGEN DEPRIVATION THERAPY + BICALUTAMIDE IN PATIENTS WITH NEWLY DIAGNOSED METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Lung A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Larynx, Lip, Oral Cavity and Pharynx RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck {CIRB}
A Window Study to assess the activity of demethylation therapy in patients with HPV positive compared with HPV negative Head and Neck Squamous Cell Carcinoma
Prostate PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Lip, Oral Cavity and Pharynx ECOG 3311: Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
ASG-22CE-13-2: A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer that Express Nectin-4
Soft Tissue ALLIANCE A091105-A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Soft Tissue RTOG 3501 (TRYHARD): A PHASE II, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF LAPATINIB (TYKERB®) FOR NON-HPV LOCALLY ADVANCED HEAD AND NECK CANCER WITH CONCURRENT CHEMORADIATION
Bladder A Phase I, open-label, multicenter, dose escalation study of oral BGJ398, a pan FGF-R kinase inhibitor, in adult patients with advanced solid malignancies.
Stomach MK-3475-040-00: A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer
Bladder MK3475-045: A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer
Bladder S1011: A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed At Time of Radial Cystectomy For Muscle Invasive Urothelial Cancer

Edit this profile

Contact Info

Hari Anant Deshpande, MD
Patient Care Locations
Yale Cancer CenterSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste 4th Floor

New Haven, CT 06511
Smilow Cancer CareYale-New Haven Hospital Saint Raphael Campus
1450 Chapel Street, Ste Suite A

New Haven, CT 06511
Mailing Address
PO Box 208028
333 Cedar Street,

New Haven, CT 06520-8028